(NASDAQ:CYTK), NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake […]

Churchill Downs Incorporated Reports 2025 Third Quarter Results GlobeNewswire October 22, 2025 LOUISVILLE, Ky., Oct. 22, 2025 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (Nasdaq: CHDN) (the “Company”, “CDI”, “we”) today reported business results for the third quarter ended September 30, 2025. Company Highlights Third quarter 2025 financial results, as compared to the prior year quarter:

Investors in V.F. Corporation Should Contact The Gross Law Firm Before November 12, 2025 to Discuss Your Rights – VFC GlobeNewswire October 22, 2025 NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of V.F. Corporation (NYSE: VFC). Shareholders who purchased shares of VFC during the

Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights – CYTK GlobeNewswire October 22, 2025 NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of

Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND; “Lindblad”; the “Company”), a global provider of expedition cruises and adventure travel experiences, will report 2025 third quarter financial results on Tuesday November 4, 2025, before the market opens. The Company will host a conference call to discuss the results at 9:00 am Eastern Time. The conference call can

Louis Pinkham, Chief Executive Officer of Regal Rexnord Corporation (NYSE: RRX), announced that the Board of Directors, at its regular quarterly meeting held on October 22, 2025, declared a dividend of $0.35 per share. The dividend is payable on January 14, 2026, to shareholders of record at the close of business on December 31, 2025.

(NASDAQ:CYTK), SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 5, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results

(NASDAQ:ARVN), NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTAC KRAS G12D degrader, will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

(AUST:TLX.AX),(NasdaqGM:TLX), MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain associated with bone metastasis. TLX090 is designed to deliver targeted

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain GlobeNewswire October 22, 2025 MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical